特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ペプチド治療薬の世界市場:2019年~2023年

Global Peptide Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 317311
出版日 ページ情報 英文 118 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.13円で換算しております。
ペプチド治療薬の世界市場:2019年~2023年 Global Peptide Therapeutics Market 2019-2023
出版日: 2018年12月24日 ページ情報: 英文 118 Pages
概要

世界のペプチド治療薬市場は、癌、糖尿病、肥満、心血管疾患などの慢性疾患の増加などにより成長しています。ペプチドはこれらの疾患の治療に高い効果を示すことが知られています。同市場は、2023年まで9%のCAGR (複合年間成長率) で拡大すると予測されています。

当レポートでは、世界のペプチド治療薬市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入するベンダーのプロファイルについてまとめています。

第1章 エグゼクティブサマリー

第2章 レポートの範囲

第3章 市況

  • 市場のエコシステム
  • 市場の特長
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模:2018年
  • 市場規模と予測:2018~2023年

第5章 ファイブフォース分析

第6章 投与ルート別市場セグメンテーション

  • 市場セグメンテーション
  • 比較
  • 非経口
  • 経口
  • その他
  • 市場の機会

第7章 適応別市場セグメンテーション

第8章 技術別市場セグメンテーション

第9章 顧客動向

第10章 地域別動向

  • 地域別セグメンテーション
  • 比較
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域
  • 主要国
  • 市場の機会

第11章 促進因子と課題

第12章 市場動向

第13章 ベンダー環境

第14章 ベンダー分析

  • 網羅されるベンダー
  • ベンダー分類
  • 市場ポジショニング
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • 武田薬品工業株式会社
  • Teva Pharmaceutical

第15章 付録

図表
  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: RoA - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by RoA
  • Exhibit 20: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by RoA
  • Exhibit 27: Market share by 2018-2023 (%)
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Decision framework
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Eli Lilly - Vendor overview
  • Exhibit 47: Eli Lilly - Business segments
  • Exhibit 48: Eli Lilly - Organizational developments
  • Exhibit 49: Eli Lilly - Geographic focus
  • Exhibit 50: Eli Lilly - Segment focus
  • Exhibit 51: Eli Lilly - Key offerings
  • Exhibit 52: Eli Lilly - Key customers
  • Exhibit 53: Novo Nordisk - Vendor overview
  • Exhibit 54: Novo Nordisk - Business segments
  • Exhibit 55: Novo Nordisk - Organizational developments
  • Exhibit 56: Novo Nordisk - Geographic focus
  • Exhibit 57: Novo Nordisk - Segment focus
  • Exhibit 58: Novo Nordisk - Key offerings
  • Exhibit 59: Novo Nordisk - Key customers
  • Exhibit 60: Sanofi - Vendor overview
  • Exhibit 61: Sanofi - Business segments
  • Exhibit 62: Sanofi - Organizational developments
  • Exhibit 63: Sanofi - Geographic focus
  • Exhibit 64: Sanofi - Segment focus
  • Exhibit 65: Sanofi - Key offerings
  • Exhibit 66: Sanofi - Key customers
  • Exhibit 67: Takeda Pharmaceutical - Vendor overview
  • Exhibit 68: Takeda Pharmaceutical - Business segments
  • Exhibit 69: Takeda Pharmaceutical - Organizational developments
  • Exhibit 70: Takeda Pharmaceutical - Geographic focus
  • Exhibit 71: Takeda Pharmaceutical - Key offerings
  • Exhibit 72: Takeda Pharmaceutical - Key customers
  • Exhibit 73: Teva Pharmaceutical - Vendor overview
  • Exhibit 74: Teva Pharmaceutical - Business segments
  • Exhibit 75: Teva Pharmaceutical - Organizational developments
  • Exhibit 76: Teva Pharmaceutical - Geographic focus
  • Exhibit 77: Teva Pharmaceutical - Segment focus
  • Exhibit 78: Teva Pharmaceutical - Key offerings
  • Exhibit 79: Teva Pharmaceutical - Key customers
  • Exhibit 80: Validation techniques employed for market sizing
  • Exhibit 81: List of abbreviations
目次
Product Code: IRTNTR30538

About this market

One of the major drivers of the global peptide therapeutics market is the growing cases of chronic diseases such as cancer, diabetes, obesity, and various cardiovascular diseases. Peptides are known to have high efficacy in the treatment of these diseases. Hence the use of peptides has increased significantly in recent years with the growing prevalence of chronic conditions. The high prevalence of chronic conditions leads to significant demand for curative drugs such as peptides thereby driving market growth. Moreover, the significant need for the treatment of these diseases has led various pharmaceutical companies to develop therapies, including peptide-based drugs. Technavio's analysts have predicted that the peptide therapeutics market will register a CAGR of almost 9% by 2023.

Market Overview

Novel drug delivery

Currently the treatment of various diseases with peptides is predominantly done by administering drugs through the parenteral route. The parenteral RoA is considered to be one of the most undesirable routes for patients due to the invasive nature of the drug administration. Hence. vendors are focusing on developing better drug delivery systems. The increasing need for novel drug delivery systems has led to the development of self-injectable pens by various vendors.

Stringent regulatory policies

One of the major challenges faced by the global peptide therapeutics market is the stringent policies set by regulatory bodies globally. The policies set for the approval of biologic drugs by regulatory bodies are more stringent than for small molecules, which makes it difficult for pharmaceutical companies to launch these drugs in the market. The late launch of drugs or FDA refusal of a drug can hinder the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the peptide therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Parenteral - Market size and forecast 2018-2023
  • Oral - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: MARKET SEGMENTATION BY INDICATION

PART 08: MARKET SEGMENTATION BY TECHNOLOGY

PART 09: CUSTOMER LANDSCAPE

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations